Senzime för investerare

Senzime develops, manufactures and markets CE- and FDA-cleared patient monitoring systems. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Presentation of Senzime’s Q4 2022 report

February 1, 14:00 CET

The presentation can be followed live at Fourth Quarter Report Presentation

Extraordinary General Meeting, February 16

The shareholders in Senzime AB (publ) are convened to an extraordinary general meeting on Thursday 16 February 2023.

Rights issue

Preliminary financial information for the development of the fourth quarter 2022 and trading update

Contact us

Want to know more?

How can Senzime’s innovative patient monitoring solutions help to eliminate in-hospital complications?
Contact us today.